î
îŒ
î
ESSA Pharma Inc
EPIX0.201USD
0.000
çµå€Â 12/19, 16:00ïŒETïŒ15åé
ãã®æ ªäŸ¡
8.93Mæ䟡ç·é¡
æ倱é¡çŽè¿12ã¶æPER
î
詳现æ å ± ESSA Pharma Inc äŒæ¥å
ESSA Pharma Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, Masofaniten (formerly EPI-7386), is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). Masofaniten is in development in combination with antiandrogen treatments in patients with prostate cancer who are earlier in their course of the disease. The Company is completing the clinical development of masofaniten as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).
ESSA Pharma Incã®äŒæ¥æ å ±
îäŒæ¥ã³ãŒãEPIX
äŒç€ŸåESSA Pharma Inc
äžå Žæ¥Feb 22, 2021
æé«çµå¶è²¬ä»»è
ãCEOãDr. David Ross Parkinson, M.D.
åŸæ¥å¡æ°35
蚌åžçš®é¡Ordinary Share
決ç®ææ«Feb 22
æ¬ç€Ÿæåšå°999 West Broadway, Suite 720
éœåžVANCOUVER
蚌åžååŒæNASDAQ Capital Market Consolidated
åœCanada
éµäŸ¿çªå·V5Z 1K5
é»è©±çªå·17783310962
ãŠã§ããµã€ãhttps://www.essapharma.com/
äŒæ¥ã³ãŒãEPIX
äžå Žæ¥Feb 22, 2021
æé«çµå¶è²¬ä»»è
ãCEOãDr. David Ross Parkinson, M.D.
ESSA Pharma Incã®çµå¶é£
îäŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
äŒç€Ÿå
äŒç€Ÿå/ããžã·ã§ã³
ããžã·ã§ã³
æ ªåŒä¿æ
å€åé¡
Mr. Jon Adkins
Mr. Jon Adkins
President, Treasurer, Secretary, Director
President, Treasurer, Secretary, Director
--
--
Mr. David Sidney Wood, CPA
Mr. David Sidney Wood, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Peter Virsik
Mr. Peter Virsik
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
--
-100.00%
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
-100.00%
åçå èš³
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
äºæ¥å¥
å°åå¥
äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
æ ªäž»
æŽæ°æå»: Fri, Oct 17
æŽæ°æå»: Fri, Oct 17
æ ªäž»çµ±èš
çš®é¡
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Xeno Acquisition Corp
100.00%
Opaleye Management Inc.
4.67%
BofA Global Research (US)
1.33%
Aldebaran Capital, LLC
1.22%
Aguja Capital GmbH
1.06%
æ ªäž»çµ±èš
æ ªäž»çµ±èš
æ¯ç
Xeno Acquisition Corp
100.00%
Opaleye Management Inc.
4.67%
BofA Global Research (US)
1.33%
Aldebaran Capital, LLC
1.22%
Aguja Capital GmbH
1.06%
çš®é¡
æ ªäž»çµ±èš
æ¯ç
Corporation
100.00%
Research Firm
5.52%
Hedge Fund
3.75%
Investment Advisor
0.85%
Venture Capital
0.10%
Investment Advisor/Hedge Fund
0.08%
æ©é¢æè³å®¶ä¿ææ ª
îæŽæ°æå»: Wed, Oct 1
æŽæ°æå»: Wed, Oct 1
å ±åæé
æ©é¢æè³å®¶æ°
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
2025Q3
79
34.87M
73.70%
-13.44M
2025Q2
91
32.28M
72.72%
-18.24M
2025Q1
96
33.48M
75.44%
-17.56M
2024Q4
101
34.20M
77.05%
-15.63M
2024Q3
97
36.44M
82.10%
-7.65M
2024Q2
110
36.54M
82.36%
-10.99M
2024Q1
138
36.33M
81.91%
-11.35M
2023Q4
143
35.77M
81.03%
-12.57M
2023Q3
161
36.59M
82.99%
-18.42M
2023Q2
177
36.37M
82.51%
-21.24M
詳现ãèŠã
æ ªäž»åå
îäŒç€Ÿå
ä¿ææ ªåŒæ°
æ¯ç
å€åé¡
å€åç
æ¥ä»
Opaleye Management Inc.
2.21M
4.67%
--
--
Jun 30, 2025
BofA Global Research (US)
627.93K
1.33%
-70.34K
-10.07%
Jun 30, 2025
Aldebaran Capital, LLC
578.94K
1.22%
+9.64K
+1.69%
Jun 30, 2025
Aguja Capital GmbH
500.00K
1.06%
--
--
Apr 30, 2025
Two Sigma Investments, LP
483.13K
1.02%
-72.09K
-12.98%
Jun 30, 2025
DLD Asset Management, LP
314.97K
0.67%
+131.31K
+71.50%
Jun 30, 2025
BNP Paribas Securities Corp. North America
271.19K
0.57%
+35.79K
+15.21%
Jun 30, 2025
LMR Partners LLP
200.00K
0.42%
+200.00K
--
Jun 30, 2025
J.P. Morgan Securities LLC
189.07K
0.4%
+24.22K
+14.69%
Jun 30, 2025
詳现ãèŠã
é¢é£ETF
îæŽæ°æå»: Mon, Oct 6
æŽæ°æå»: Mon, Oct 6
éæå
æ¯ç
Avantis US Small Cap Equity ETF
0%
Avantis US Small Cap Equity ETF
æ¯ç0%
é åœé
îéå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã
æ¥ä»
é
åœé
æš©å©ç¢ºå®æ¥
æ¯ææ¥
é
åœèœã¡æ¥
ããŒã¿ãªã
æ ªåŒåå²
îæ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
æ¥ä»
çš®é¡
æ¯ç
ããŒã¿ãªã
ãããã質å
ESSA Pharma Incã®äžäœ5åã®æ ªäž»ã¯èª°ã§ããïŒ
îESSA Pharma Incã®äžäœ5åã®æ ªäž»ã¯ä»¥äžã®ãšããã§ãã
Opaleye Management Inc.ã¯2.21Mæ ªãä¿æããŠãããããã¯å šäœã®4.67%ã«çžåœããŸãã
BofA Global Research (US)ã¯627.93Kæ ªãä¿æããŠãããããã¯å šäœã®1.33%ã«çžåœããŸãã
Aldebaran Capital, LLCã¯578.94Kæ ªãä¿æããŠãããããã¯å šäœã®1.22%ã«çžåœããŸãã
Aguja Capital GmbHã¯500.00Kæ ªãä¿æããŠãããããã¯å šäœã®1.06%ã«çžåœããŸãã
Two Sigma Investments, LPã¯483.13Kæ ªãä¿æããŠãããããã¯å šäœã®1.02%ã«çžåœããŸãã
Opaleye Management Inc.ã¯2.21Mæ ªãä¿æããŠãããããã¯å šäœã®4.67%ã«çžåœããŸãã
BofA Global Research (US)ã¯627.93Kæ ªãä¿æããŠãããããã¯å šäœã®1.33%ã«çžåœããŸãã
Aldebaran Capital, LLCã¯578.94Kæ ªãä¿æããŠãããããã¯å šäœã®1.22%ã«çžåœããŸãã
Aguja Capital GmbHã¯500.00Kæ ªãä¿æããŠãããããã¯å šäœã®1.06%ã«çžåœããŸãã
Two Sigma Investments, LPã¯483.13Kæ ªãä¿æããŠãããããã¯å šäœã®1.02%ã«çžåœããŸãã
ESSA Pharma Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯äœã§ããïŒ
îESSA Pharma Incã®æ ªäž»ã¿ã€ãäžäœ3çš®ã¯ã
Xeno Acquisition Corp
Opaleye Management Inc.
BofA Global Research (US)
Xeno Acquisition Corp
Opaleye Management Inc.
BofA Global Research (US)
ESSA Pharma IncïŒEPIXïŒã®æ ªåŒãä¿æããŠããæ©é¢ã®æ°ã¯ããã€ã§ããïŒ
î2025Q3æç¹ã§ãESSA Pharma Incã®æ ªåŒãä¿æããŠããæ©é¢ã¯79瀟ãããä¿ææ ªåŒã®ç·åžå ŽäŸ¡å€ã¯çŽ34.87Mã§ãå
šäœã®73.70%ãå ããŠããŸãã2025Q2ãšæ¯èŒããŠãæ©é¢ã®æã¡æ ªã¯0.98%å¢å ããŠããŸãã
ESSA Pharma Incã®æ倧ã®åçæºã¯äœã§ããïŒ
î--ã«ãããŠã--éšéãESSA Pharma Incã«ãšã£ãŠæ倧ã®åçãçã¿åºããŠããããã®éé¡ã¯--ã§ãå
šåçã®--%ãå ããŠããŸãã
